Publications
Publications
Show Results For
- All HBS Web
(1,283)
- Faculty Publications (525)
Page 1 of 525
Results →
- May 2025
- Supplement
Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (D)
By: Linda A. Hill and Lydia Begag
This fourth installment in the Pfizer Global Clinical Supply (GCS) transformation case series highlights how over a decade of cultural and digital evolution positioned GCS to meet unprecedented global challenges. In 2011, Michael Ku became the Vice President of GCS and... View Details
- May 2025
- Case
Daiichi Sankyo: Steering a Global Organization
In the spring of 2023, Sunao Manabe, CEO of Daiichi Sankyo, reflected on a pivotal decision. A large Western pharmaceutical company had made a bid to partner with Daiichi Sankyo to develop the next three products in its oncology pipeline. Daiichi Sankyo, a 125-year old... View Details
Keywords: Strategy; Culture Change; Decision-making; Leadership; Culture; Innovation; Psychological Safety
- April 2025
- Case
Radical Transformation at Bayer: Dynamic Shared Ownership
By: Boris Groysberg and Gamze Yucaoglu
In 2023, Bill Anderson became CEO of Bayer AG, a 160-year-old life sciences giant looking to strengthen its pharma pipeline, manage debt, and cut through bureaucracy. His bold response: Dynamic Shared Ownership (DSO), a radical model replacing traditional hierarchies... View Details
- March 2025
- Teaching Note
Gavi and the 'Next' Pandemic
By: Tarun Khanna and Samir Junnarkar
Teaching Note for HBS Case No. 725-351. View Details
- January 2025 (Revised March 2025)
- Case
Gavi and the 'Next' Pandemic
By: Tarun Khanna and Kerry Herman
In 2025, CEO Dr. Sania Nishtar and her team consider the lessons the Global Alliance for Vaccine and Immunizations (GAVI) learned from the pandemic. GAVI successfully brought COVID-19 vaccines to large swaths of the undeveloped and under-developed world by pooling... View Details
- November 2024
- Teaching Note
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details
Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States; District of Columbia
- October 2024 (Revised February 2025)
- Case
Lanco Medical Group: Fostering Happiness for Growth
By: Susanna Gallani, Jenyfeer Martínez Buitrago and Katherine Sonnefeldt
This case describes how Lanco Medical Group, a fast-growing pharmaceutical distributor serving Latin America, approached the design of their employee benefits and incentives program. After learning about gaps between what leadership believed motivated employees and... View Details
- October 2024
- Case
Parexel: Scaling Up and Industry Dynamics
By: Regina E. Herzlinger and Ben Creo
Through the lens of biopharmaceutical contract research organization (CRO) PAREXEL, this case traces the evolution of the firm as it reinvents itself in response to the transformation of the CRO sector from a small, secondary cluster of firms into a major player with... View Details
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
- August 2024 (Revised February 2025)
- Case
Novo Nordisk Foundation
By: Debora L. Spar and Julia M. Comeau
In 2024, Novo Nordisk A/S was one of the most profitable firms in the world, thanks largely to just two GLP-1-based drugs, Ozempic and Wegovy. Unusually, this incredibly profitable firm was controlled not by individual private shareholders, but by a non-profit... View Details
Keywords: Pharmaceutical Companies; Diabetes; Obesity; Foundation; Non-profit Management; Profit; Corporate Governance; Business or Company Management; Corporate Social Responsibility and Impact; Expansion; Philanthropy and Charitable Giving; Nonprofit Organizations; Pharmaceutical Industry; Denmark; Europe
- September 2024
- Article
Comprehensive Measurement of Biopharmaceutical R&D Investment
By: Amitabh Chandra, John Drum, Michael Daly, Henry Mirsberger, Samuel Spare, Ulrich Neumann, Silas Martin and Noam Kirson
- August 2024
- Article
How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
- June 2024 (Revised December 2024)
- Case
Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital
By: Joshua D. Margolis and Ahmed Dahawy
Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details
Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Pharmaceutical Industry; Pharmaceutical Industry; Jordan
- June 2024
- Supplement
Legacy Partners (A)
By: Richard S. Ruback and Royce Yudkoff
Instructors should consider the timing of making videos available to students, as they may reveal key case details.
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021.... View Details
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021.... View Details
Keywords: Acquisition; Small Business; Cost vs Benefits; Decisions; Corporate Entrepreneurship; Leadership Style; Leading Change; Business or Company Management; Problems and Challenges; Health Care and Treatment; Health Disorders; Medical Specialties; Nutrition; Supply Chain Management; Growth Management; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; California
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details
- 18 Apr 2024
- Lecture
Innovation Opportunities Created by COVID-19 Can Help: And How to Make Them Happen
The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Pharmaceutical Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
- April 2024 (Revised November 2024)
- Case
Moderna: Pioneering a People Platform to Accelerate Science Innovation
By: Tatiana Sandino, Emil Dy and Samuel Grad
Moderna was founded in 2010 to explore how messenger ribonucleic acid (mRNA) could be used to create breakthrough medicines by encoding instructions for the body to create antibodies. When Stéphane Bancel (HBS 2000) took over in 2011, he bet on the potential of this... View Details
Keywords: Disruptive Innovation; Talent and Talent Management; Selection and Staffing; AI and Machine Learning; Digital Strategy; Innovation and Management; Leadership Development; Management Practices and Processes; Management Systems; Organizational Culture; Performance Evaluation; Alignment; Employee Relationship Management; Science-Based Business; Expansion; Pharmaceutical Industry; Pharmaceutical Industry; United States
- March 2024 (Revised July 2024)
- Case
WeightWatchers: Promoting Weight Health
In December 2023, the 60-year-old weight management industry stalwart WeightWatchers announced the launch of WeightWatchers Clinic, which incorporated GLP-1s , a new class of prescription weight-loss medications, into the company’s portfolio of products and mobile app... View Details
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details